Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a ...

Both non-small lung cancer and small cell lung cancer is a disease that now has various therapeutic options available, ...

If there is ever an annual follow up CT scan that does not cause me significant anxiety, this year will be the one.

Dr. Joshua K. Sabari and Jackie Herigodt sat down to discuss the importance of knowing a patient beyond their cancer diagnosis.